Home

Shukra Pharmaceuticals Ltd PE Ratio

Image

Shukra Pharmaceuticals Ltd

NSE: SHUKRAPHARMA

PE

59.3

Last updated on: Jan 15, 2025

Key Highlights

  • The P/E Ratio of Shukra Pharmaceuticals Ltd is 59.3 as of 15 Jan 9.00 AM .
  • The P/E Ratio of Shukra Pharmaceuticals Ltd changed from 203.3 on March 2020 to 19.3 on March 2024 . This represents a CAGR of -37.56% over 5 years.
  • The Latest Trading Price of Shukra Pharmaceuticals Ltd is ₹ 195.65 as of 15 Jan 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.

Historical P/E Ratio of Shukra Pharmaceuticals Ltd

No data available

Company Fundamentals for Shukra Pharmaceuticals Ltd

Image

Shukra Pharmaceuticals Ltd

NSE: SHUKRAPHARMA

Share Price

₹ 195.65

3.80 (1.98%)

stock direction

Last updated on: Jan 15, 2025

Market Price of Shukra Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Shukra Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
15 Jan 2025195.65
14 Jan 2025191.85
13 Jan 2025188.1
10 Jan 2025184.45
09 Jan 2025180.85
08 Jan 2025177.35
07 Jan 2025173.9
06 Jan 2025165.65
03 Jan 2025157.8
02 Jan 2025150.3

SWOT Analysis Of Shukra Pharmaceuticals Ltd

Strength

1

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Shukra Pharmaceuticals Ltd

Asset Value vs Market Value of Shukra Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Shukra Pharmaceuticals Ltd856.71
Sun Pharmaceuticals Industries Ltd421527
Divis Laboratories Ltd156037
Cipla Ltd116854
Dr Reddys Laboratories Ltd111746

PE Ratio of Shukra Pharmaceuticals Ltd Explained

``

856.71

Market cap

14

Earnings

59.3X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Shukra Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Shukra Pharmaceuticals Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Shukra Pharmaceuticals Ltd

No data available

* All values are in %

About Shukra Pharmaceuticals Ltd

  • Shukra Pharmaceuticals Limited (Formerly known Relish Pharmaceuticals Limited) was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
  • The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
  • Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

Shukra Pharmaceuticals Ltd News Hub

Shukra Pharmaceuticals standalone net profit rises 16.67% in the June 2024 quarter

Net profit of Shukra Pharmaceuticals rose 16.67% to Rs 0.49 crore in the quarter ended June 2024 as

Read more

13 Aug 2024

Shukra Pharmaceuticals to discuss results

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 202

Read more

05 Aug 2024

Shukra Pharmaceuticals to hold AGM

Shukra Pharmaceuticals announced that the 31th Annual General Meeting (AGM) of the company will be h

Read more

16 Sep 2024

Shukra Pharmaceuticals schedules board meeting

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 September

Read more

24 Sep 2024

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Shukra Pharmaceuticals Ltd

What is the current PE Ratio of Shukra Pharmaceuticals Ltd?

The Current PE Ratio of Shukra Pharmaceuticals Ltd is 59.29 as on 15 Jan 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 15 Jan 2025.

What was the PE Ratio of Shukra Pharmaceuticals Ltd last year?

The PE Ratio of Shukra Pharmaceuticals Ltd was 4.17 last year, now the PE ratio is 59.29, showing a year-on-year growth of 1321.8%.

What does the PE Ratio of Shukra Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Shukra Pharmaceuticals Ltd is 59.29. This ratio indicates that investors are willing to pay 59.29 times the earnings per share for each share of Shukra Pharmaceuticals Ltd.

What is the PE Ratio Growth of Shukra Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Shukra Pharmaceuticals Ltd grew by 1321.8% whereas, the EPS ratio grew by 127.3.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions